Featured News
414Wire StoriesTAE Life Sciences Announces First Cancer Patient Treatments Using Accelerator-Based Biologically Targeted Radiation Therapy (BNCT)
Patients underwent BNCT using TAE Life Sciences’ Neutron Beam System as part of Neuboron Medical Group’s NeuPex System at Xiamen Humanity Hospital...
- 659Wire Stories
TAE Life Sciences Announces First Cancer Patient Treatments Using Accelerator-Based Biologically Targeted Radiation Therapy (BNCT)
Patients underwent BNCT using TAE Life Sciences’ Neutron Beam System as part of Neuboron Medical Group’s NeuPex System at Xiamen Humanity Hospital...
- 426Wire Stories
Anteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts
Company Funded Through Results of U.S. Early Feasibility Study of DurAVR™ BRISBANE, Australia and EAGAN, Minn.–(BUSINESS WIRE)–Anteris Technologies Ltd (ASX: AVR), a...
- 424Wire Stories
Anteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts
Company Funded Through Results of U.S. Early Feasibility Study of DurAVR™ BRISBANE, Australia and EAGAN, Minn.–(BUSINESS WIRE)–Anteris Technologies Ltd (ASX: AVR), a...
- 442Wire Stories
Anteris Announces Completion of A$35 Million Capital Raise and Provides 2023 Goalposts
Company Funded Through Results of U.S. Early Feasibility Study of DurAVR™ BRISBANE, Australia and EAGAN, Minn.–(BUSINESS WIRE)–Anteris Technologies Ltd (ASX: AVR), a...
- 426Wire Stories
VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B
BI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed Initial data suggest VBI-2601 (BRII-179) and BRII-835 combination...
- 419Wire Stories
VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B
BI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed Initial data suggest VBI-2601 (BRII-179) and BRII-835 combination...
- 411Wire Stories
VBI Vaccines Announces Presentation of Interim Phase 2 Data Evaluating Combination of VBI-2601 (BRII-179) and BRII-835 for the Treatment of Chronic Hepatitis B
BI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed Initial data suggest VBI-2601 (BRII-179) and BRII-835 combination...
- 520Wire Stories
Asahi Kasei Completes Second Plant for Ceolus™ Microcrystalline Cellulose
NEW YORK & DÜSSELDORF, Germany & TOKYO–(BUSINESS WIRE)–#asahikasei–Asahi Kasei, a diversified Japanese multinational company, has completed the construction of its second plant...
- 445Wire Stories
Asahi Kasei Completes Second Plant for Ceolus™ Microcrystalline Cellulose
NEW YORK & DÜSSELDORF, Germany & TOKYO–(BUSINESS WIRE)–#asahikasei–Asahi Kasei, a diversified Japanese multinational company, has completed the construction of its second plant...
- 446Wire Stories
Asahi Kasei Completes Second Plant for Ceolus™ Microcrystalline Cellulose
NEW YORK & DÜSSELDORF, Germany & TOKYO–(BUSINESS WIRE)–#asahikasei–Asahi Kasei, a diversified Japanese multinational company, has completed the construction of its second plant...
